Literature DB >> 16962885

Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia.

Iain C Macdougall1, Kai-Uwe Eckardt.   

Abstract

As with many other therapeutic areas in modern-day medicine, scientific advances in drug development (using such techniques as recombinant DNA technology, site-directed mutagenesis, pegylation of molecules, peptide library screening, and gene transfer) have resulted in the development of potential new agents and strategies for stimulating erythropoiesis. These advances are of possible benefit in treating anaemia due to various causes, including chronic renal failure. Several new treatments will soon become clinically available, while others are at present at an early stage of development but are nevertheless of scientific interest. We review these new therapeutic strategies, and discuss at what stage some of the newer products are in relation to their clinical development programme.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16962885     DOI: 10.1016/S0140-6736(06)69120-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  27 in total

Review 1.  Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.

Authors:  Dirk J van Veldhuisen; Stefan D Anker; Piotr Ponikowski; Iain C Macdougall
Journal:  Nat Rev Cardiol       Date:  2011-05-31       Impact factor: 32.419

2.  Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.

Authors:  Wanja M Bernhardt; Michael S Wiesener; Paul Scigalla; James Chou; Roland E Schmieder; Volkmar Günzler; Kai-Uwe Eckardt
Journal:  J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 10.121

Review 3.  Cardiovascular effects of erythropoietin an update.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Zvonimir S Katusic
Journal:  Adv Pharmacol       Date:  2010

Review 4.  Stimulating erythropoiesis in inflammatory bowel disease associated anemia.

Authors:  Georgia Tsiolakidou; Ioannis-E Koutroubakis
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 5.  Erythropoietin: physiology and molecular mechanisms.

Authors:  Robert N Foley
Journal:  Heart Fail Rev       Date:  2008-01-31       Impact factor: 4.214

Review 6.  Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.

Authors:  Monique P Curran; Paul L McCormack
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  HIF-prolyl hydroxylases in the rat kidney: physiologic expression patterns and regulation in acute kidney injury.

Authors:  Johannes Schödel; Bernd Klanke; Alexander Weidemann; Björn Buchholz; Wanja Bernhardt; Marko Bertog; Kerstin Amann; Christoph Korbmacher; Michael Wiesener; Christina Warnecke; Armin Kurtz; Kai-Uwe Eckardt; Carsten Willam
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

Review 8.  Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach.

Authors:  Zahra Moradi; Amirhosein Maali; Javad Sadeghi Shad; Alireza Farasat; Reza Kouchaki; Mona Moghadami; Mohamad Hosein Ahmadi; Mehdi Azad
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-16       Impact factor: 0.900

Review 9.  The role of anemia management in improving outcomes for African-Americans with chronic kidney disease.

Authors:  Janice P Lea; Keith Norris; Lawrence Agodoa
Journal:  Am J Nephrol       Date:  2008-04-24       Impact factor: 3.754

10.  Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice.

Authors:  Yusuke Sasaki; Mariko Noguchi-Sasaki; Yukari Matsuo-Tezuka; Yuki Matsumoto-Omori; Mitsue Kurasawa; Keigo Yorozu; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2014-03-13       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.